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Abstract
Background: Circulating tumour cells (CTCs) are increasingly being used in the surveillance of cancer,
allowing for potential early detection and real-time monitoring of disease progression. The presence of
CTCs in patients with metastatic cutaneous head and neck squamous cell carcinoma (cHNSCC) has not
been evaluated. Results: CTCs were detected in eight of ten patients with regional metastatic cHNSCC
(80%; range 1-44 cells/9 mL blood). CTMs were detected in three of ten patients (30%, range 1-4 cells/9
mL blood). Methods: Preoperative blood samples from ten patients with nodal metastases from
cutaneous squamous cell carcinomas (cSCC) were analyzed using the IsoFluxTM System for the
detection and enumeration of CTCs and circulating tumour microemboli (CTMs). Conclusions: For the
first time CTCs have been detected in patients with nodal metastases from cHNSCC. Further work is
required to understand their prognostic significance and potential to directly influence clinical practice.
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Abstract
Background: Circulating tumour cells (CTCs) are increasingly being used in the
surveillance of cancer, allowing for potential early detection and real-time monitoring
of disease progression. The presence of CTCs in patients with metastatic cutaneous
head and neck squamous cell carcinoma (cHNSCC) has not been evaluated.
Results: CTCs were detected in eight of ten patients with regional metastatic
cHNSCC (80%; range 1–44 cells/9 mL blood). CTMs were detected in three of ten
patients (30%, range 1–4 cells/9 mL blood).
Methods: Preoperative blood samples from ten patients with nodal metastases
from cutaneous squamous cell carcinomas (cSCC) were analyzed using the IsoFluxTM
System for the detection and enumeration of CTCs and circulating tumour microemboli
(CTMs).
Conclusions: For the first time CTCs have been detected in patients with nodal
metastases from cHNSCC. Further work is required to understand their prognostic
significance and potential to directly influence clinical practice.
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Introduction

Results

Australia has the highest incidence of skin cancer
worldwide, with two in every three Australians developing
this debilitating disease in their lifetime. Australians are
four times more likely to develop skin cancer than any
other form of cancer [1, 2]. Non-melanoma skin cancer
(NMSC) accounts for over 430,000 new cases each year;
with 138,000 (20–25%) being squamous cell carcinoma
(cSCC) [2, 3]. In 2010 alone, there were 445 deaths as a
result of NMSC, predominately SCC [4].
UV radiation is the most significant risk factor
for cSCC, with the majority of NMSCs located on sunexposed areas of the body, particularly the head and neck
(70%) [1, 5]. cSCC accounts for 20% of all head and neck
malignancies [6].
Treatment of primary lesions includes surgical
resection, with the addition of adjuvant radiation therapy
in advanced disease [7]. Currently, adjuvant chemotherapy
is employed infrequently outside of a trial setting. Despite
aggressive first line treatment, approximately 5% of cSCC
cases develop nodal metastases [7]. Whilst relatively
uncommon, 70% of metastases occur within the first 12
months following treatment of the primary lesion, with a
poor prognosis and 5-year overall survival rate of 11% in
patients with distant metastases [7–10].
The early identification of patients at higher
risk for metastatic spread would help rationalise the
need for surveillance. Currently, other than traditional
histopathologic assessment [11], little is understood about
the potential for metastasis in cSCC.
Carcinomas spread by lymphatic and/or vascular
infiltration giving rise to circulating tumour cells (CTCs)
that are shed from the primary tumour [12]. These CTCs
may exist individually or as microemboli, are readily
detectable in the peripheral blood and are increasingly
being used in surveillance in breast, lung, colorectal
(CRC) and prostate cancer [13]. Subpopulations of
tumours may have the ability to enter the vascular space
by mesenchymal transition (Epithelial Mesenchymal
Transition). Once in the vascular space, tumour cells
have the opportunity to metastasize to distant sites
(Mesenchymal Epithelial Transition). The detection of the
CTCs is a snapshot of this process. As noted by Grisanti
[14] CTCs have the potential to provide ‘real-time’
monitoring acting as ‘liquid biopsies’. CTC estimation
may allow real-time monitoring of disease progression or
reoccurrence and earmark some patients for a change or
reintroduction of treatment. No studies have as yet focused
on CTCs as markers for primary or metastatic cSCC. This
pilot study aimed to preoperatively identify the presence
of CTCs in patients with nodal metastases from cSCC in
the head and neck prior to surgery.

A summary of patient characteristics and results is
provided in Table 1. All patients had previously undergone
primary tumour resection and had no evidence of distant
metastatic disease (M0). The IsoFluxTM System was able to
detect the presence of CTCs in eight of ten patients (80%)
with cell counts ranging from 1–44 in 9 mL of blood.
In addition, CTC microemboli clusters (CTMs) were
detected in three patients (30%), with the highest CTC
and CTM counts attributed to the same patient. All ten
patients were treated with curative intent by surgery, and
eight of ten received adjuvant radiotherapy. Two patients
succumbed to their disease within the study period. Both
of these patients had undetectable CTCs and CTMs at the
time of blood collection.
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Discussion
Detectable CTCs have shown implications for
disease-free survival, overall survival, risk of local
reoccurrence and risk of metastases in subgroups of other
solid tumour groups [15]. However no studies have as yet
focused on CTCs as markers for primary or metastatic
disease in patients with cSCC. This is the first study to
examine the presence of CTCs in metastatic cSCC.
CTCs were identified in eight of ten patients with
metastatic cSCC using the IsoFluxTM System. We also
identified circulating tumour microemboli clusters (CTM)
in three of ten patients.
Numerous prospective studies have now shown
a significant association between CTCs and worsening
metastatic disease, with baseline CTCs acting as strong
predictors of decreased survival, independent of other
factors in breast, prostate and colorectal cancer [13].
Notably, Jatana [15] demonstrated improved disease-free
survival in patients with no detectable CTCs in mucosal
HNSCC. However, in another study, the absence of CTCs
preoperatively did not necessarily portend a favourable
outcome in mucosal HNSCC [16]. These authors also
reported that the only patient (of 16) where no CTCs were
identified later succumbed to locoregional and distant
metastatic disease. Interestingly, in our series, there has
been no correlation between the presence of CTCs and
patient outcome in the early stages of follow-up. Indeed,
during the 12-month follow-up period, both patients
who died (5 months and 8 months post surgery) had no
recordable CTCs in their preoperative blood sample. Both
patients had recurrent post radiotherapy disease at the time
of CTC sampling.
Whilst we were successful in detecting CTCs, the
levels detected were quite small in comparison to other
studies [15]. As noted by Grisanti [14], this may reflect
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Table 1: Patient summary and circulating tumour cell and microemboli results
Patient

Age

Sex

Pathology

1
2
3
4
5
6
7
8
9
10

85
67
69
77
62
77
88
78
54
66

M
M
M
M
M
M
M
M
M
M

cSCC
cSCC
cSCC
cSCC
cSCC
cSCC
cSCC
cSCC
cSCC
cSCC

Nodal
stage
N2b
N2a
N2a
N2a
N2a
N1
N2b
N1
N2b
N3

Histopathology
grade
G3
G3
G3
G3
G3
G3
G3
G2
G1
G3

CTM
count
2
0
0
1
4
0
0
0
0
0

Materials and Methods

a genuine low count due to the extremely rare nature of
CTCs in the blood (estimations of 1 in 100 million to 1
in one billion blood cells). Alternatively, it may represent
a falsely low count as a result of the absence of Ep-Cam
and cytokeratin expression on CTCs displaying greater
mesenchymal morphology [14].
Notably, an additional patient enrolled in the study
was excluded from analysis due to deviation from the
experimental protocol because blood was collected intraoperatively. This collection produced interesting results
with this patient having much higher CTCs/CTMs counts
detected (86 and 25, respectively). These findings echo
those of previous animal models which have shown
correlation between disseminated cancer cells as a result
of surgical manipulation of tumour, and is paralleled by
human studies which have displayed increased counts
of CTCs intraoperatively compared to pre- and postoperative counts in surgical removal of colorectal liver
metastases [17, 18]. Once again, this highlights the effect
of surgery on CTC number, although the significance of
this is elusive.
We have identified the presence of Ep-CAM and
cytokeratin expressing cells in the circulation of patients
with metastatic cSCC. A broadening of CTC markers in
a positive selection model using mesenchymal and novel
biomarkers may show higher levels, and may add to our
understanding of the metastatic process in cSCC. As cSCC
is the most common malignancy with metastatic potential,
the ability to identify the small percentage of patients
where metastases occur would have enormous public
health implications, particularly in regions with high
solar exposure. The establishment of CTCs as markers for
metastatic disease also has the potential to directly inform
clinical practice by early identification of recurrence and
the development of individualized treatment pathways for
patients with high-risk disease.

www.impactjournals.com/oncotarget

CTC
count
4
0
19
14
44
14
1
4
1
0

Treatment
Surgery
Radiation
therapy
Yes
Adjuvant
Yes
Adjuvant
Yes
Adjuvant
Yes
Adjuvant
Yes
Adjuvant
Yes
Adjuvant
Yes
Prior
Yes
Prior
Yes
Adjuvant
Yes
Adjuvant

Patient selection
Ethics approval was obtained from the UOW/
ISLHD Human Research Ethics Committee (HE14/397).
Inclusion criteria were patients who were candidates for
surgical treatment of metastatic cSCC affecting the lymph
nodes of the parotid and/or neck. Eleven patients were
enrolled, with one patient excluded from analysis due to a
major deviation from the experimental protocol.

Blood collection
Peripheral blood samples of 9mL were collected and
drawn into anti-coagulant K3 EDTA coated tubes (Vacuette
455036; Greiner Bio-One, Interpath Services, VIC,
Australia) at the time of cannulation immediately preoperatively. Blood samples were kept at room temperature
and processed within 24 hours of collection, using the
IsoFluxTM System according to manufactures instructions
and protocol established by Harb [19].

Sample preparation and CTC isolation
White cell fraction (WCC) was isolated using
LeucoSep tubes (Greiner Bio-One, Interpath Services,
VIC, Australia) prepared with 15.2 mL of Ficoll-Paque
PLUS (GE Healthcare, NSW, Australia), recovered, then
res-suspended in phosphate-buffered saline (PBS) binding
buffer. Pre-conjugated immunomagnetic beads (with
Anti-EpCAM antibodies; CTC Enrichment kit Fluxion
Biosciences Inc.) were added and the sample incubated on
a rotator at 4°C for 1.5 hours. Samples were loaded into
the microfluidic cartridge of the IsoFluxTM System and
processed for 45 minutes, with magnetically labelled target
cells captured, isolated and recovered for further processing.
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CTC enumeration and imaging

6. Goh R, Bova R, Fogarty G. Cutaneous squamous cell
carcinoma metastatic to parotid-analysis of prognostic
factors and treatment outcome. World Journal of Surgical
Oncology. 2012; 10:117.

Recovered cells were fixed (PBS containing 1.8%
formaldehyde), washed and blocked with 10% normal
donkey serum, then stained with anti-CD45 antibody
(CTC Enumeration Kit, Fluxion Biosciences, Inc.), Cy3conjugated secondary antibody, and permeabilised with
0.1% Triton X-100. Following this, cells were further
stained with FITC conjugated anti-cytokeratin antibody
(CK; CTC Enumeration Kit, Fluxion Biosciences Inc.),
mounted with Hoechst 33342 (Mounting Media; CTC
Enrichment Kit, Fluxion Biosciences Inc.), transferred to
a SensoPlate Glass-Bottom Multiwell Plate (Grenier BioOne, Interpath Services, VIC, Australia) and stored in 4°
for up to 2 weeks for imaging. As per protocol, cells were
counted as CTCs if they were CK+, and CD45–, nucleated,
and morphologically intact. Imaging was performed using
an inverted Olympus IX71 microscope (Olympus Australia
Pty. Ltd., Victoria, Australia) and Proscan II automatic
scanning (Prior Scientific Inc., Massachusetts, USA).

7. D’Souza J, Clark J. Management of the neck in metastatic
cutaneous squamous cell carcinoma of the head and neck.
Current Opinion in Otolaryngology & Head and Neck
Surgery. 2011; 19:99–105.
8. Brunner M, Ng B, Veness M, Clark J. Comparison of the
prognostic value of the AJCC N staging system in mucosal
and cutaneous squamous cell carcinoma. Oral Oncology.
2013; 49:S12.
9. Brunner M, Veness M, Ch’ng S, Elliot M, Clark J. Distant
metastases from cutaneous squamous cell carcinoma—
analysis of AJCC stage IV. Head & Neck. 2013; 35:72–75.
10. Clark J, Rumcheva P, Veness M. Analysis and comparison
of the 7th Edition AJCC nodal staging system for metastatic
cutaneous squamous cell carcinoma of the head and neck.
Annals of Surgical Oncology. 2012; 19:4252–4258.
11. Gore S, Shaw D, Martin R, Kelder W, Roth K, Uren R,
Gao K, Davies S, Ashford B, Ngo Q, Shannon K, Clark
J. Prospective study of sentinel node biopsy for high risk
cutaneous squamous cell carcinoma of the head and neck.
Head & Neck. 2016; 38 Suppl 1:E884-9. doi: 10.1002/
hed.24120.
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